|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 7 (October 1), 1999:
pp. 2208-2216
Risk of Lymphoproliferative Disorders After Bone Marrow
Transplantation: A Multi-Institutional Study
Rochelle E. Curtis,
Lois B. Travis,
Philip A. Rowlings,
Gérard Socié,
Douglas W. Kingma,
Peter M. Banks,
Elaine S. Jaffe,
George E. Sale,
Mary M. Horowitz,
Robert P. Witherspoon,
Donna
A. Shriner,
Daniel J. Weisdorf,
Hans-Jochem Kolb,
Keith M. Sullivan,
Kathleen A. Sobocinski,
Robert Peter Gale,
Robert N. Hoover,
Joseph
F. Fraumeni Jr, and
H. Joachim Deeg
From the Division of Cancer Epidemiology and Genetics, and the
Division of Cancer Biology and Diagnosis, Laboratory of Pathology,
National Cancer Institute, Bethesda, MD; International Bone Marrow
Transplant Registry, Medical College of Wisconsin, Milwaukee, WI; Fred
Hutchinson Cancer Research Center, Seattle, WA; Hôpital Saint
Louis, Hématologie-Greffe de Moelle, Paris, France; Carolinas
Medical Center, Charlotte, NC; University of Minnesota Medical School,
Minneapolis, MN; Universität München, Munich, Germany; and
Salick Health Care, Inc, Los Angeles, CA.
We evaluated 18,014 patients who underwent allogeneic bone marrow
transplantation (BMT) at 235 centers worldwide to examine the incidence
of and risk factors for posttransplant lymphoproliferative disorders
(PTLD). PTLD developed in 78 recipients, with 64 cases occurring less
than 1 year after transplantation. The cumulative incidence of PTLD was
1.0% ± 0.3% at 10 years. Incidence was highest 1 to 5 months
posttransplant (120 cases/10,000 patients/yr) followed by a steep
decline to less than 5/10,000/yr among  1-year survivors. In
multivariate analyses, risk of early-onset PTLD (<1 year) was strongly associated (P < .0001) with unrelated or human
leukocyte antigen (HLA) mismatched related donor (relative risk
[RR] = 4.1), T-cell depletion of donor marrow (RR = 12.7), and use of antithymocyte globulin (RR = 6.4) or anti-CD3
monoclonal antibody (RR = 43.2) for prophylaxis or treatment of acute
graft-versus-host disease (GVHD). There was a weaker association with
the occurrence of acute GVHD grades II to IV (RR = 1.9, P = .02) and with conditioning regimens that included radiation (RR = 2.9, P = .02). Methods of T-cell depletion that selectively
targeted T cells or T plus natural killer (NK) cells were associated
with markedly higher risks of PTLD than methods that removed both T and
B cells, such as the CAMPATH-1 monoclonal antibody or elutriation
(P = .009). The only risk factor identified for late-onset
PTLD was extensive chronic GVHD (RR = 4.0, P = .01). Rates
of PTLD among patients with 2 or 3 major risk factors were 8.0% ± 2.9% and 22% ± 17.9%, respectively. We conclude that factors
associated with altered immunity and T-cell regulatory mechanisms are
predictors of both early- and late-onset PTLD.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
O. Landgren, E. S. Gilbert, J. D. Rizzo, G. Socie, P. M. Banks, K. A. Sobocinski, M. M. Horowitz, E. S. Jaffe, D. W. Kingma, L. B. Travis, et al.
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
Blood,
May 14, 2009;
113(20):
4992 - 5001.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Ambinder
Evaluation of T- and NK-Cell-Targeted Therapies: Is There a Role for Rituximab Prophylaxis?
Clin. Cancer Res.,
April 1, 2009;
15(7):
2205 - 2206.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Baldanti, M. Gatti, M. Furione, S. Paolucci, C. Tinelli, P. Comoli, P. Merli, and F. Locatelli
Kinetics of Epstein-Barr Virus DNA Load in Different Blood Compartments of Pediatric Recipients of T-Cell-Depleted HLA-Haploidentical Stem Cell Transplantation
J. Clin. Microbiol.,
November 1, 2008;
46(11):
3672 - 3677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Davies, J. G. Gribben, L. L. Brennan, D. Yuk, L. M. Nadler, and E. C. Guinan
Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies
Blood,
September 15, 2008;
112(6):
2232 - 2241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Hollingsworth, D. P. Frush, J. Kurtzburg, and V. K. Prasad
Pediatric Hematopoietic Stem Cell Transplantation and the Role of Imaging
Radiology,
August 1, 2008;
248(2):
348 - 365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Majhail
Old and New Cancers after Hematopoietic-Cell Transplantation
Hematology,
January 1, 2008;
2008(1):
142 - 149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Gotze, D. Hoffmann, H. M. Schatzl, C. Peschel, F. Fend, and T. Decker
Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR Inhibitor for relapsed chronic lymphocytic leukemia
Haematologica,
September 1, 2007;
92(9):
1282 - 1283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Juvonen, S. Aalto, J. Tarkkanen, L. Volin, K. Hedman, and T. Ruutu
Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients
Haematologica,
June 1, 2007;
92(6):
819 - 825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Pillai, T. I. George, S. Dutt, P. Teo, and S. Strober
Host NKT Cells Can Prevent Graft-versus-Host Disease and Permit Graft Antitumor Activity after Bone Marrow Transplantation
J. Immunol.,
May 15, 2007;
178(10):
6242 - 6251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Flynn and D. S. Kaufman
Donor cell leukemia: insight into cancer stem cells and the stem cell niche
Blood,
April 1, 2007;
109(7):
2688 - 2692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Perrine, O. Hermine, T. Small, F. Suarez, R. O'Reilly, F. Boulad, J. Fingeroth, M. Askin, A. Levy, S. J. Mentzer, et al.
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies
Blood,
March 15, 2007;
109(6):
2571 - 2578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. G. Brunstein, D. J. Weisdorf, T. DeFor, J. N. Barker, J. Tolar, J.-A. H. van Burik, and J. E. Wagner
Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation
Blood,
October 15, 2006;
108(8):
2874 - 2880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sandherr, H. Einsele, H. Hebart, C. Kahl, W. Kern, M. Kiehl, G. Massenkeil, O. Penack, X. Schiel, S. Schuettrumpf, et al.
Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO)
Ann. Onc.,
July 1, 2006;
17(7):
1051 - 1059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Delgado, K. Thomson, N. Russell, J. Ewing, W. Stewart, G. Cook, S. Devereux, R. Lovell, R. Chopra, D. I. Marks, et al.
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study
Blood,
February 15, 2006;
107(4):
1724 - 1730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lotze, F. Schuler, W. H. Kruger, C. Hirt, M. Kirsch, S. Vogelgesang, C. A. Schmidt, and G. Dolken
Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: Case study
Neuro-oncol,
October 1, 2005;
7(4):
508 - 510.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. L. Syrjala, S. L. Langer, J. R. Abrams, B. E. Storer, and P. J. Martin
Late Effects of Hematopoietic Cell Transplantation Among 10-Year Adult Survivors Compared With Case-Matched Controls
J. Clin. Oncol.,
September 20, 2005;
23(27):
6596 - 6606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Curtis, C. Metayer, J. D. Rizzo, G. Socie, K. A. Sobocinski, M. E. D. Flowers, W. D. Travis, L. B. Travis, M. M. Horowitz, and H. J. Deeg
Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study
Blood,
May 15, 2005;
105(10):
3802 - 3811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Miller, Y. Soignier, A. Panoskaltsis-Mortari, S. A. McNearney, G. H. Yun, S. K. Fautsch, D. McKenna, C. Le, T. E. Defor, L. J. Burns, et al.
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
Blood,
April 15, 2005;
105(8):
3051 - 3057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Paulsen, M. M. Rosenkilde, J. Eugen-Olsen, and T. N. Kledal
Epstein-Barr Virus-Encoded BILF1 Is a Constitutively Active G Protein-Coupled Receptor
J. Virol.,
January 1, 2005;
79(1):
536 - 546.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. Spitzer
Haploidentical Stem Cell Transplantation: The Always Present but Overlooked Donor
Hematology,
January 1, 2005;
2005(1):
390 - 395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Islas-Ohlmayer, A. Padgett-Thomas, R. Domiati-Saad, M. W. Melkus, P. D. Cravens, M. d. P. Martin, G. Netto, and J. V. Garcia
Experimental Infection of NOD/SCID Mice Reconstituted with Human CD34+ Cells with Epstein-Barr Virus
J. Virol.,
December 15, 2004;
78(24):
13891 - 13900.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Beynet, S. A. Wee, S. S. Horwitz, S. Kohler, S. Horning, R. Hoppe, and Y. H. Kim
Clinical and Pathological Features of Posttransplantation Lymphoproliferative Disorders Presenting With Skin Involvement in 4 Patients
Arch Dermatol,
September 1, 2004;
140(9):
1140 - 1146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Rivailler, A. Carville, A. Kaur, P. Rao, C. Quink, J. L. Kutok, S. Westmoreland, S. Klumpp, M. Simon, J. C. Aster, et al.
Experimental rhesus lymphocryptovirus infection in immunosuppressed macaques: an animal model for Epstein-Barr virus pathogenesis in the immunosuppressed host
Blood,
September 1, 2004;
104(5):
1482 - 1489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Kotloff, V. N. Ahya, and S. W. Crawford
Pulmonary Complications of Solid Organ and Hematopoietic Stem Cell Transplantation
Am. J. Respir. Crit. Care Med.,
July 1, 2004;
170(1):
22 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Wagner, Y. C. Cheng, M. H. Huls, A. P. Gee, I. Kuehnle, R. A. Krance, M. K. Brenner, C. M. Rooney, and H. E. Heslop
Prompt versus preemptive intervention for EBV lymphoproliferative disease
Blood,
May 15, 2004;
103(10):
3979 - 3981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. Shorr, G. M. Susla, and N. P. O'Grady
Pulmonary Infiltrates in the Non-HIV-Infected Immunocompromised Patient: Etiologies, Diagnostic Strategies, and Outcomes
Chest,
January 1, 2004;
125(1):
260 - 271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Orjuela, T. G. Gross, Y.-K. Cheung, B. Alobeid, E. Morris, and M. S. Cairo
A Pilot Study of Chemoimmunotherapy (Cyclophosphamide, Prednisone, and Rituximab) in Patients with Post-Transplant Lymphoproliferative Disorder following Solid Organ Transplantation
Clin. Cancer Res.,
September 1, 2003;
9(10):
3945S - 3952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mohty, J.-O. Bay, C. Faucher, B. Choufi, K. Bilger, O. Tournilhac, N. Vey, A.-M. Stoppa, D. Coso, C. Chabannon, et al.
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen
Blood,
July 15, 2003;
102(2):
470 - 476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Meij, J. W. J. van Esser, H. G. M. Niesters, D. van Baarle, F. Miedema, N. Blake, A. B. Rickinson, I. Leiner, E. Pamer, B. Lowenberg, et al.
Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease
Blood,
June 1, 2003;
101(11):
4290 - 4297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Baker, T. E. DeFor, L. J. Burns, N. K.C. Ramsay, J. P. Neglia, and L. L. Robison
New Malignancies After Blood or Marrow Stem-Cell Transplantation in Children and Adults: Incidence and Risk Factors
J. Clin. Oncol.,
April 1, 2003;
21(7):
1352 - 1358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C.M. Straathof, C. M. Bollard, C. M. Rooney, and H. E. Heslop
Immunotherapy for Epstein-Barr Virus-Associated Cancers in Children
Oncologist,
February 1, 2003;
8(1):
83 - 98.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Braziel, M. A. Shipp, A. L. Feldman, V. Espina, M. Winters, E. S. Jaffe, E. F. Petricoin III, and L. A. Liotta
Molecular Diagnostics
Hematology,
January 1, 2003;
2003(1):
279 - 293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Nicolls, M. Coulombe, J. Beilke, H. C. Gelhaus, and R. G. Gill
CD4-Dependent Generation of Dominant Transplantation Tolerance Induced by Simultaneous Perturbation of CD154 and LFA-1 Pathways
J. Immunol.,
November 1, 2002;
169(9):
4831 - 4839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Perez-Simon, P. D. Kottaridis, R. Martino, C. Craddock, D. Caballero, R. Chopra, J. Garcia-Conde, D. W. Milligan, S. Schey, A. Urbano-Ispizua, et al.
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders
Blood,
October 16, 2002;
100(9):
3121 - 3127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. McSweeney, R. A. Nash, K. M. Sullivan, J. Storek, L. J. Crofford, R. Dansey, M. D. Mayes, K. T. McDonagh, J. L. Nelson, T. A. Gooley, et al.
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes
Blood,
August 13, 2002;
100(5):
1602 - 1610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. J. van Esser, H. G. M. Niesters, B. van der Holt, E. Meijer, A. D. M. E. Osterhaus, J. W. Gratama, L. F. Verdonck, B. Lowenberg, and J. J. Cornelissen
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation
Blood,
May 29, 2002;
99(12):
4364 - 4369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Carpenter, F. R. Appelbaum, L. Corey, H. J. Deeg, K. Doney, T. Gooley, J. Krueger, P. Martin, S. Pavlovic, J. Sanders, et al.
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
Blood,
April 15, 2002;
99(8):
2712 - 2719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. C. Gartner, H. Schafer, K. Marggraff, G. Eisele, M. Schafer, K. Roemer, H.-J. Laws, M. Sester, U. Sester, H. Einsele, et al.
Evaluation of Use of Epstein-Barr Viral Load in Patients after Allogeneic Stem Cell Transplantation To Diagnose and Monitor Posttransplant Lymphoproliferative Disease
J. Clin. Microbiol.,
February 1, 2002;
40(2):
351 - 358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Wingard, G. B. Vogelsang, and H. J. Deeg
Stem Cell Transplantation: Supportive Care and Long-Term Complications
Hematology,
January 1, 2002;
2002(1):
422 - 444.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. Luznik, S. Jalla, L. W. Engstrom, R. Iannone, and E. J. Fuchs
Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide
Blood,
December 1, 2001;
98(12):
3456 - 3464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. D. Berg, N. K. Brinster, K. M. Huhn, M. G. Goggins, R. J. Jones, A. Makary, K. M. Murphy, C. A. Griffin, L. S. Rosenblum-Vos, M. J. Borowitz, et al.
Transmission of a T-Cell Lymphoma by Allogeneic Bone Marrow Transplantation
N. Engl. J. Med.,
November 15, 2001;
345(20):
1458 - 1463.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. J. van Esser, B. van der Holt, E. Meijer, H. G. M. Niesters, R. Trenschel, S. F. T. Thijsen, A. M. van Loon, F. Frassoni, A. Bacigalupo, U. W. Schaefer, et al.
Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT
Blood,
August 15, 2001;
98(4):
972 - 978.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Haddad, S. Paczesny, V. Leblond, J.-M. Seigneurin, M. Stern, A. Achkar, M. Bauwens, V. Delwail, D. Debray, C. Duvoux, et al.
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial
Blood,
March 15, 2001;
97(6):
1590 - 1597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Tiberghien, C. Ferrand, B. Lioure, N. Milpied, R. Angonin, E. Deconinck, J.-M. Certoux, E. Robinet, P. Saas, B. Petracca, et al.
Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft
Blood,
January 1, 2001;
97(1):
63 - 72.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. D. Groves, M. S. Linet, L. B. Travis, and S. S. Devesa
Cancer Surveillance Series: Non-Hodgkin's Lymphoma Incidence by Histologic Subtype in the United States From 1978 Through 1995
J Natl Cancer Inst,
August 2, 2000;
92(15):
1240 - 1251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Koehne, H. F. Gallardo, M. Sadelain, and R. J. O'Reilly
Rapid selection of antigen-specific T lymphocytes by retroviral transduction
Blood,
July 1, 2000;
96(1):
109 - 117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Socie, R. E. Curtis, H. J. Deeg, K. A. Sobocinski, A. H. Filipovich, L. B. Travis, K. M. Sullivan, P. A. Rowlings, D. W. Kingma, P. M. Banks, et al.
New Malignant Diseases After Allogeneic Marrow Transplantation for Childhood Acute Leukemia
J. Clin. Oncol.,
January 14, 2000;
18(2):
348 - 348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Greiner, J. O. Armitage, and T. G. Gross
Atypical Lymphoproliferative Diseases
Hematology,
January 1, 2000;
2000(1):
133 - 146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Majewski, M. Korecka, P. Kossev, S. Li, J. Goldman, J. Moore, L. E. Silberstein, P. C. Nowell, W. Schuler, L. M. Shaw, et al.
The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders
PNAS,
April 11, 2000;
97(8):
4285 - 4290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
